PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis

NYSE:MD • US58502B1061

18.82 USD
-0.48 (-2.49%)
At close: Feb 20, 2026
18.4 USD
-0.42 (-2.23%)
After Hours: 2/20/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Overall MD gets a fundamental rating of 5 out of 10. We evaluated MD against 102 industry peers in the Health Care Providers & Services industry. MD has only an average score on both its financial health and profitability. MD is cheap, but on the other hand it scores bad on growth. These ratings would make MD suitable for value investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year MD was profitable.
  • In the past year MD had a positive cash flow from operations.
  • In multiple years MD reported negative net income over the last 5 years.
  • Of the past 5 years MD 4 years had a positive operating cash flow.
MD Yearly Net Income VS EBIT VS OCF VS FCFMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B

1.2 Ratios

  • MD's Return On Assets of 7.37% is amongst the best of the industry. MD outperforms 89.22% of its industry peers.
  • The Return On Equity of MD (18.21%) is better than 86.27% of its industry peers.
  • With an excellent Return On Invested Capital value of 10.25%, MD belongs to the best of the industry, outperforming 80.39% of the companies in the same industry.
  • MD had an Average Return On Invested Capital over the past 3 years of 7.83%. This is in line with the industry average of 9.00%.
  • The last Return On Invested Capital (10.25%) for MD is above the 3 year average (7.83%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.37%
ROE 18.21%
ROIC 10.25%
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
MD Yearly ROA, ROE, ROICMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80 -100

1.3 Margins

  • MD's Profit Margin of 8.44% is amongst the best of the industry. MD outperforms 89.22% of its industry peers.
  • Looking at the Operating Margin, with a value of 12.20%, MD belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
  • MD's Operating Margin has declined in the last couple of years.
Industry RankSector Rank
OM 12.2%
PM (TTM) 8.44%
GM N/A
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MD Yearly Profit, Operating, Gross MarginsMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MD is still creating some value.
  • MD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MD Yearly Shares OutstandingMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
MD Yearly Total Debt VS Total AssetsMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

  • An Altman-Z score of 2.09 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • MD has a Altman-Z score of 2.09. This is comparable to the rest of the industry: MD outperforms 51.96% of its industry peers.
  • MD has a debt to FCF ratio of 2.20. This is a good value and a sign of high solvency as MD would need 2.20 years to pay back of all of its debts.
  • MD has a better Debt to FCF ratio (2.20) than 76.47% of its industry peers.
  • MD has a Debt/Equity ratio of 0.65. This is a neutral value indicating MD is somewhat dependend on debt financing.
  • MD has a Debt to Equity ratio (0.65) which is in line with its industry peers.
  • Even though the debt/equity ratio score it not favorable for MD, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 2.2
Altman-Z 2.09
ROIC/WACC1.21
WACC8.47%
MD Yearly LT Debt VS Equity VS FCFMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

  • MD has a Current Ratio of 1.83. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
  • MD has a better Current ratio (1.83) than 72.55% of its industry peers.
  • MD has a Quick Ratio of 1.83. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.83, MD is in the better half of the industry, outperforming 74.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.83
Quick Ratio 1.83
MD Yearly Current Assets VS Current LiabilitesMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.24%, which is quite impressive.
  • Measured over the past years, MD shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.01% on average per year.
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.71%

3.2 Future

  • Based on estimates for the next years, MD will show a small growth in Earnings Per Share. The EPS will grow by 1.48% on average per year.
  • Based on estimates for the next years, MD will show a small growth in Revenue. The Revenue will grow by 4.60% on average per year.
EPS Next Y10.99%
EPS Next 2Y8.08%
EPS Next 3Y2.62%
EPS Next 5Y1.48%
Revenue Next Year2.7%
Revenue Next 2Y2.49%
Revenue Next 3Y4.56%
Revenue Next 5Y4.6%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MD Yearly Revenue VS EstimatesMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B
MD Yearly EPS VS EstimatesMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 9.27 indicates a reasonable valuation of MD.
  • Compared to the rest of the industry, the Price/Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 94.12% of the companies listed in the same industry.
  • MD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.99.
  • A Price/Forward Earnings ratio of 8.35 indicates a reasonable valuation of MD.
  • 94.12% of the companies in the same industry are more expensive than MD, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.06, MD is valued rather cheaply.
Industry RankSector Rank
PE 9.27
Fwd PE 8.35
MD Price Earnings VS Forward Price EarningsMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MD indicates a rather cheap valuation: MD is cheaper than 88.24% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of MD indicates a rather cheap valuation: MD is cheaper than 91.18% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 5.91
EV/EBITDA 6.5
MD Per share dataMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of MD may justify a higher PE ratio.
PEG (NY)0.84
PEG (5Y)0.93
EPS Next 2Y8.08%
EPS Next 3Y2.62%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • MD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PEDIATRIX MEDICAL GROUP INC

NYSE:MD (2/20/2026, 8:04:00 PM)

After market: 18.4 -0.42 (-2.23%)

18.82

-0.48 (-2.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-19
Earnings (Next)05-04
Inst Owners98.9%
Inst Owner Change-0.24%
Ins Owners1.87%
Ins Owner Change-2.29%
Market Cap1.62B
Revenue(TTM)N/A
Net Income(TTM)162.19M
Analysts78.67
Price Target23.12 (22.85%)
Short Float %3.33%
Short Ratio4.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.41%
Min EPS beat(2)21.14%
Max EPS beat(2)39.68%
EPS beat(4)4
Avg EPS beat(4)32.13%
Min EPS beat(4)21.14%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)18.68%
EPS beat(12)7
Avg EPS beat(12)8.95%
EPS beat(16)9
Avg EPS beat(16)6.72%
Revenue beat(2)1
Avg Revenue beat(2)-0.77%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)0.42%
Revenue beat(4)2
Avg Revenue beat(4)-0.67%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-2.24%
Revenue beat(12)2
Avg Revenue beat(12)-2.22%
Revenue beat(16)3
Avg Revenue beat(16)-2.43%
PT rev (1m)0%
PT rev (3m)35.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3%
EPS NY rev (1m)0%
EPS NY rev (3m)16.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.13%
Valuation
Industry RankSector Rank
PE 9.27
Fwd PE 8.35
P/S 0.84
P/FCF 5.91
P/OCF 5.57
P/B 1.81
P/tB N/A
EV/EBITDA 6.5
EPS(TTM)2.03
EY10.79%
EPS(NY)2.25
Fwd EY11.97%
FCF(TTM)3.18
FCFY16.91%
OCF(TTM)3.38
OCFY17.94%
SpS22.39
BVpS10.37
TBVpS-4.42
PEG (NY)0.84
PEG (5Y)0.93
Graham Number21.76
Profitability
Industry RankSector Rank
ROA 7.37%
ROE 18.21%
ROCE 12.98%
ROIC 10.25%
ROICexc 13.79%
ROICexgc 251.95%
OM 12.2%
PM (TTM) 8.44%
GM N/A
FCFM 14.22%
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexgc growth 3Y26.95%
ROICexgc growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 2.2
Debt/EBITDA 2.24
Cap/Depr 72.01%
Cap/Sales 0.86%
Interest Coverage 250
Cash Conversion 112.59%
Profit Quality 168.57%
Current Ratio 1.83
Quick Ratio 1.83
Altman-Z 2.09
F-Score8
WACC8.47%
ROIC/WACC1.21
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
EPS Next Y10.99%
EPS Next 2Y8.08%
EPS Next 3Y2.62%
EPS Next 5Y1.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.71%
Revenue Next Year2.7%
Revenue Next 2Y2.49%
Revenue Next 3Y4.56%
Revenue Next 5Y4.6%
EBIT growth 1Y42.45%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year70.96%
EBIT Next 3Y20.58%
EBIT Next 5YN/A
FCF growth 1Y104.91%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y73.9%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%

PEDIATRIX MEDICAL GROUP INC / MD FAQ

What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?

ChartMill assigns a fundamental rating of 5 / 10 to MD.


What is the valuation status for MD stock?

ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.


How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?

PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 6 / 10.


What are the PE and PB ratios of PEDIATRIX MEDICAL GROUP INC (MD) stock?

The Price/Earnings (PE) ratio for PEDIATRIX MEDICAL GROUP INC (MD) is 9.27 and the Price/Book (PB) ratio is 1.81.